Welcome to the e-CCO Library!

P469: Changes in peripheral blood lymphocyte subsets induced by azathioprine in Crohn’s disease patients
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Labidi*, M. Fekih, N. Ben Mustapha, S. Ben Amor, M. Serghini, L. Kallel, J. Boubaker, A. Filali

Created: Friday, 22 February 2019, 9:49 AM
P469: Effect of mirikizumab on clinical and endoscopic outcomes based on prior advanced therapy failure in patients with moderately to severely active ulcerative colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Navabi, S.(1)*;D'Haens, G.(2);Samaan, K.H.(3);Li, X.(3);Arora, V.(3);Redondo, I.(3);Danese, S.(4);
Created: Friday, 14 July 2023, 11:05 AM
P469: Effectiveness of dose optimisation by pre-genotyping NUDT 15 R139C on reducing thiopurine-induced leucopoenia in Chinese patients with Crohn’s disease: a randomised controlled trial
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Chao*1, L. Lin1, Y. Huang2, C. Zhang3, J. Huang1, Q. Cao2, X. Gao1, K. Chao1

Created: Friday, 22 February 2019, 9:41 AM
P469: Infliximab for induction of medically-induced remission in Crohn's disease: a Cochrane systematic review
Year: 2022
Source: ECCO'22
Authors: Radford, S.(1);Sinopoulou, V.(2);Gordon, M.(2);Eldragini, M.E.A.A.(1);Darie, A.M.(1);Akobeng, A.(3);Moran, G.W.(1);
Created: Friday, 11 February 2022, 3:52 PM
P469: Safety, tolerability, and pharmacokinetics of the intestine-restricted oral pan-Janus kinase inhibitor TD-1473 after single and multiple oral doses in healthy subjects
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ferslew B.*1, Sherman C.2, Nguyen D.3, Graham R.1

Created: Wednesday, 20 February 2019, 10:36 AM
P469: Self-reported cutaneous side effects of anti-TNF therapy in inflammatory bowel disease patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Ridge1*, C. Gallagher2, C. Judge1, J. Campion1, D. Mc Namara2,3,4, D. Kevans1,3,4

Created: Thursday, 21 February 2019, 9:14 AM
P469: The PROPER study: interim analysis of a pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn’s disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Dignass, A.(1);Gisbert, J.(2);Freudensprung, U.(3);Addison, J.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P470 The concept of illness identity in inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

L.L. Knödler1, A. Thomann2, M.P. Ebert2, S. Lis3, W. Reindl2

Created: Thursday, 30 January 2020, 10:12 AM
P470: Comparative effectiveness analysis of flares, hospitalisations, and corticosteroid use among biologic naïve patients with inflammatory bowel disease within 12 months of initiation of vedolizumab or infliximab
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Alam N.1, Raluy-Callado M.1, Gardstein B.2, Curtis R.3, Khalid J.M.*3

Created: Wednesday, 20 February 2019, 10:36 AM
P470: DUBLIN (Degree of Ulcerative colitis Burden of Luminal INflammation) score, a simple method to quantify inflammatory burden in ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. R. Rowan*1, G. Cullen1, H. E. Mulcahy1, J. Sheridan1, A. C. Moss2,3, E. J. Ryan1, G. A. Doherty1

Created: Friday, 22 February 2019, 9:41 AM
P470: Early change in faecal calprotectin during anti-TNFα initiation is strongly predictive of outcome in Crohn’s disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

P. Pavlidis*, G. Chung- Faye, P. Dubois, I. Bjarnason, B. H. Hayee

Created: Friday, 22 February 2019, 9:49 AM
P470: Evolution of asymptomatic unresected lesions in patients operated for multifocal Crohn's disease.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Abdalla, S.(1)*;Lelievre, O.(2);Carbonnel, F.(3);Penna, C.(4);Benoist, S.(5);Brouquet, A.(5);
Created: Friday, 14 July 2023, 11:05 AM
P470: Improving IBD-related pregnancy knowledge with a specialised preconception and pregnancy in IBD clinic
Year: 2018
Source: ECCO '18 Vienna
Authors:

N. Rodriguez, L. Ambrosio, L. Dieleman, B. Halloran, K.I. Kroeker, F. Peerani, K. Wong, R.N. Fedorak, V.W. Huang*

Created: Thursday, 21 February 2019, 9:14 AM
P470: Real-world characteristics and complications of patients with Ulcerative Colitis receiving conventional therapy in the public healthcare system in Brazil
Year: 2022
Source: ECCO'22
Authors: Galhardi Gasparini, R.(1);Yukie Sassaki, L.(2);Lima Martins, A.(3);Saad Hossne, R.(4);Watanabe de Oliveira, R.(5);Yang Santos, C.(6);Biatti Barreto, T.(7);
Created: Friday, 11 February 2022, 3:52 PM
P470: Ustekinumab Trough Levels are not Associated with Clinical Response in Inflammatory Bowel Disease Patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Zelinkova, Z.(1);Lipovska, A.(2);Otottova, K.(2);Lucenicova, J.(3);Kadleckova, B.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P471 What is the appropriate cut-off value of CRP to predict endoscopic remission in ulcerative colitis patients with clinical remission?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Shin, G. Seong, J.H. Song, S.M. Kong, T.J. Kim, E.R. Kim, S.N. Hong, D.K. Chang, Y.H. Kim

Created: Thursday, 30 January 2020, 10:12 AM
P471: A Transcriptome-dependent Prognostic Model of Response in Patients with Ulcerative Colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Johnson, T.(1);Reinisch, W.(2);Steere, B.(3);Milch, C.(4);Harris, C.(3);Morris, N.(3);D'Haens, G.(5);Huang, K.(1);Krishnan, V.(3)*;
Created: Friday, 14 July 2023, 11:05 AM
P471: Association of vedolizumab levels with clinical and biochemical markers of inflammation during maintenance therapy in inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Plevris*1, G. R. Jones1, P. W. Jenkinson1, C. S. Chuah1, M. Lyons1, L. M. Merchant1, R. J. Pattenden1, I. D. Arnott1, C. W. Lees1

Created: Friday, 22 February 2019, 9:41 AM
P471: Clinical characteristics and complications in hospitalised elderly patients with ulcerative colitis in a real-world specialised hospital
Year: 2018
Source: ECCO '18 Vienna
Authors:

Y. Kita1*, A. Fujimori1, R. Koshiba1, K. Fujimoto1, T. Sato1, M. Kawai2, K. Kamikozuru1, T. Takagawa2, Y. Yukoyama1, T. Miyazaki1, K. Watanabe2, N. Hida1, S. Nakamura1

Created: Thursday, 21 February 2019, 9:14 AM
P471: Efficacy and safety of switching from reference infliximab to biosimilar infliximab in patients with inflammatory bowel disease: first French experience
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Soret P.-A.*1,2, Prieux-Klotz C.1, Avouac J.3, Molto A.3, Dior M.1, Brieau B.1, Dreanic J.1, Camus M.1, Barret M.1, Coriat R.1, Conort O.4, Chast F.4, Goulvestre C.5, Le Jeunne C.6, Dougados M.3, Nahon S.2, Chaussade S.1, Abitbol V.1

Created: Wednesday, 20 February 2019, 10:36 AM